Alpha 2.0
Login Register
» Articles » PMID: 29333925

Androgen Receptor-independent Prostate Cancer: an Emerging Clinical Entity

Overview
Journal Cancer Biol Ther
Specialties Oncology
Pharmacology
Date 2018 Jan 16
PMID 29333925
Citations 3
Authors
Ilyas Sahin
Anthony E Mega
Benedito A Carneiro
Affiliations
Soon will be listed here.
Abstract

Androgen deprivation therapy remains the backbone of prostate cancer treatment given its pivotal role in the pathogenesis of prostate cancer. The growing knowledge of androgen receptor-independent (i.e. AR-null) prostate cancer cells, however, might advance the treatment paradigm of prostate cancer. Here, we examined the results of two recent studies, published in Cancer Cell by Bluemn and Shukla et al., and their impact in the future management of castration-resistant prostate cancer.

Citing Articles

Regulates the Transcription of AR Target Genes by Antagonizing NONO.

Lu Y, Wan X, Huang W, Zhang L, Luo J, Li D Life (Basel). 2021; 11(11).

PMID: 34833084 PMC: 8625561. DOI: 10.3390/life11111208.

Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.

Oner E, Kotmakci M, Baird A, Gray S, Debelec Butuner B, Bozkurt E J Nanobiotechnology. 2021; 19(1):71.

PMID: 33685469 PMC: 7938557. DOI: 10.1186/s12951-021-00781-z.

RAP80 expression in breast cancer and its relationship with apoptosis in breast cancer cells.

Jin G, Mao X, Qiao Z, Chen B, Jin F Onco Targets Ther. 2019; 12:625-634.

PMID: 30705591 PMC: 6343510. DOI: 10.2147/OTT.S186981.

References
1.
Vandekerkhove G, Chi K, Wyatt A . Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Cancer Genet. 2017; 228-229:151-158. DOI: 10.1016/j.cancergen.2017.08.003. View
2.
Shukla S, Cyrta J, Murphy D, Walczak E, Ran L, Agrawal P . Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell. 2017; 32(6):792-806.e7. PMC: 5728174. DOI: 10.1016/j.ccell.2017.10.008. View
3.
Saraon P, Drabovich A, Jarvi K, Diamandis E . Mechanisms of Androgen-Independent Prostate Cancer. EJIFCC. 2016; 25(1):42-54. PMC: 4975190. View
4.
Cattrini C, Zanardi E, Vallome G, Cavo A, Cerbone L, Di Meglio A . Targeting androgen-independent pathways: new chances for patients with prostate cancer?. Crit Rev Oncol Hematol. 2017; 118:42-53. DOI: 10.1016/j.critrevonc.2017.08.009. View
5.
Shah R, Mehra R, Chinnaiyan A, Shen R, Ghosh D, Zhou M . Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004; 64(24):9209-16. DOI: 10.1158/0008-5472.CAN-04-2442. View